Biomarkers are proteins, hormones, or pieces of DNA that can be released by cancer cells or by your body in response to cancer, which may be tested for.
Lung
Advancements in Lung Cancer Treatment Provide Hope for Patients
Receiving a lung cancer diagnosis can be overwhelming, and you may have questions about your options and what comes next.
Lung Cancer
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)
Cancer Discovery
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
The New England Journal of Medicine
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
Journal of Clinical Oncology
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Clinical Cancer Research
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
Nature Reviews. Clinical Oncology
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Targeted Oncology
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
Esmo Open
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma